Salt loss in newborns: beyond common adrenal issues
Part of Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at babies who lose too much salt (hyponatremia) due to hormone problems in the first two months of life. It aims to learn more about conditions other than the common one (21-hydroxylase deficiency).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a blood sodium level below 130 mEq/L (low salt).
- The salt loss started between birth and 60 days old.
- You were born between January 1, 1989 and December 31, 2023.
- You were cared for at the special center running this study.
- You do not have 21-hydroxylase deficiency (a common adrenal problem).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at fertility and sexual function in people with congenital adrenal hyperplasia (CAH), a condition affecting hormone production. It aims to understand how CAH impacts these areas.
This study follows people who may have too much “androgen” (a hormone) to learn what causes it and how it changes over time. You may be followed even if the exact cause is not yet known, and your results may help doctors better understand these conditions.
This study looks back at medical records of young children who had a condition called pseudohypoaldosteronism (a temporary salt-wasting problem) along with a urinary tract malformation or infection. Researchers want to learn more about this condition to help doctors recognize and treat it better.
This early-phase study looks at natural body chemicals (uric acid and klotho) and how sensitive your blood pressure may be to salt. It may help researchers understand long-term health risks in people born very early.
This observational study measures how body fluid and electrolytes change in adults with low blood sodium caused by low “tonicity” (not diluted by high sugar or other causes). It may help clinicians better understand which treatment approaches keep sodium levels safer and more stable.
This study tests a new medicine called crinecerfont in children under 4 years old with classic congenital adrenal hyperplasia (CAH), a condition where the body doesn't make certain hormones properly. Researchers want to learn if the medicine is safe and how it works in the body.
Hear when a new Neonatal Salt Loss trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.